ClinicalTrials.gg
Status unknownNCT01857128Updated May 20, 2013

Pilonidal Disease Wound Healing Study

A Phase 4 interventional study of Drawtex dressing and Negative Pressure Wound Therapy in Pilonidal Disease, sponsored by Walter Reed National Military Medical Center. Status unknown at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-05-20.

Sponsored by Walter Reed National Military Medical Center · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2013), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of the study is to learn about the best way to treat pilonidal cyst wounds and learn which type of bandage (or dressing) can help the wound heal faster after having surgery.

Read the detailed description

This pilot study is a prospective randomized open-label study examining the efficacy of Drawtex® Hydroconductive wound dressing and negative pressure wound therapy(NPWT) in pilonidal cystectomy wound healing by secondary intention.

Pilonidal disease has a significant impact on the active duty demographic and the treatments for this disease result in a substantial cost to the military in both duty days lost and for the medical care provided. This study examines Negative Pressure Wound Therapy (NPWT) and the Drawtex® Hydroconductive Dressing for the treatment of surgical wounds resulting from limited excision of pilonidal disease. This clinical trial is a prospective, randomized open label examination of two standard wound therapy modalities with the goal of determining which treatment promotes the most rapid wound healing by secondary intention. Secondary goals include determining which treatment is most cost effective and is most acceptable to patients.

Active duty, retired, and dependent adults (age 18-60 years) who are scheduled to undergo limited surgical cyst excision will be recruited from patients who are referred to the General Surgery Department at Walter Reed National Military Medical Center (WRNMMC). Health care providers in the General Surgery Department will be informed about the study and requested to refer appropriate patients to the study Investigators for evaluation and potential inclusion in the study. The informed consent process will occur at WRNMMC, General Surgery Clinic during the pre-operative clinic visit(s). If the patient consents to screening for inclusion in the study, then they will be assigned a subject number and randomly assigned to a study arm, either NPWT or Drawtex®, preoperatively. The subject will then undergo a limited excision of the pilonidal cyst. If the resulting wound post-surgery meets enrollment criteria, then the subject will be enrolled in the study. At this point, the randomization arm will be revealed either NPWT or Drawtex® dressing. Wound care will be done at the wound care clinic two times a week (biweekly) for approximately 4 weeks or until there is 75% epithelialization, and then on a weekly and then on a monthly basis until 100% epithelialization of the wound or 270 days of follow up are reached. Wound healing progress will be evaluated objectively using a digital planimetry analysis system and blinded evaluators. Secondary objectives include adverse events, bacterial load, expression of inflammatory markers, cost to military and patient satisfaction assessments,

02

Conditions studied

  • Pilonidal Disease
03

In context

Lead sponsor

Walter Reed National Military Medical Center is the lead sponsor of 78 studies on the registry; 20 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 3 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult male or non-lactating female age 18 to 60 years inclusive.
  2. Diagnosis of pilonidal disease with cyst requiring surgery, with undermining to remove the cyst and requiring limited excision with healing by secondary intension.
  3. Presence of chronic symptomatic pilonidal disease defined as at least one pilonidal sinus and a history of at least two acute pilonidal abscesses or persistent symptoms altering patient's quality of life.
  4. Military active duty members need a supervisor signed memorandum to participate (Active Duty Supervisor's Approval Memo).
  5. Understands the purpose and risks of study by scoring 80% or higher on knowledge assessment test.
  6. Available and willing to participate for the duration of the study (approximately 30-270 days maximum depending on time to wound healing).
  7. Available and willing to provide written informed consent.
  8. Able and willing to follow instructions as per protocol.
  9. Available for all visits as per protocol. Post Surgery Study Enrollment Criteria
  10. Post-surgical wound measurement (length x width x depth):

(cm x 1.5 cm x 1.5 cm)greater than or equal to 3 cm in length, greater than or equal to 1.5 cm in width, and greater than or equal to1.5 cm in depth.

Rationale: satisfies the minimum size wound that NPWT may be employed.

Exclusion criteria

Exclusion Criteria:

  1. Does not meet all inclusion criteria.
  2. Pregnant (by history or as ascertained by pregnancy test) or lactating female Rationale: immune modulation and potential for altered healing trajectory as well as operative risk to fetus for elective procedure.
  3. Known HIV infection.
  4. Known immunodeficiency or currently receiving immunosuppressive therapy (inhaled and topical steroids are allowed).
  5. Autoimmune disease (clinical, preexisting anti-dsDNA antibodies 30 IU, or positive ANA ELISA with a titer greater than 1:80 on pre-operative screening) Exclusionary medical histories will include the following diagnoses: systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, progressive systemic sclerosis, Sjogren's syndrome, polymyositis/ dermatomyositis, and vasculitis Rationale: potential for altered wound healing.
  6. Acute or chronic, clinically significant cardiac, pulmonary, hepatic, or renal abnormality, as determined by physical examination or basic laboratory screening performed at pre-operative evaluation.
  7. Known documented history of diabetes mellitus.
  8. Non-ambulatory or limited mobility. Rationale: non ambulatory patients may have altered wound healing in the sacral area due to constant pressure from positioning.
  9. History of current tobacco use: defined as cigarette smoking greater than or equal to one half pack (10 cigarettes) per day:

    Rationale: confounding factor prolonging wound healing.

  10. Complex pilonidal disease determined by the surgeon to require a procedure other than the study procedure for appropriate treatment of the disease.
  11. Acute pilonidal abscess or infection within 6 weeks of planned operative date.
  12. Concerns for arterial bleeding or cancer in the wound bed or in the vicinity of the dressing.
  13. Any other significant finding which, in the opinion of the investigator, would increase the subject's risk of having an adverse outcome from participating in this protocol.
  14. Lack of or unwillingness to provide/sign informed consent. Post Surgery Exclusion Study Criteria
  15. Post-surgical wound measurement restrictions (enth x width x depth):

(0 cm x 10 cm x 6 cm)greater than or equal to 10 cm in length, greater than or equal to 10 cm in width OR greater than or equal to 6 cm in depth. If bone is visible or exposed, the subject must be excluded.

Rationale: large wounds are deemed complex and wounds with exposed or visible bone require antibiotic therapy.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Drawtex Hydroconductive Dressing

    Gauze-like dressing placed onto wound

    Device: Drawtex dressing

  • Active comparator
    Negative Pressure Wound Therapy

    Usual care including vacuum and canister

    Device: Negative Pressure Wound Therapy

Interventions

  • DeviceDrawtex dressing
  • DeviceNegative Pressure Wound Therapy
06

What researchers measure

Primary outcomes

  1. Time to wound healing

    Time (days) to 100% epithelialization of the wound bed will be evaluated using digitized planimetry in a random manner by two independent evaluators blinded to the study treatment.

    Time frame: Up to 270 days or 9 months

07

Study locations

1 of 1 sites recruiting
  • Walter Reed National Military Medical Center -Dept of General Surgery
    Bethesda, Maryland 20889, United States
    Recruiting
    • Michael P McNally, M.D. · Contactmichael.p.mcnally.mil@health.mil · 301-295-4442
    • John S Maddox, M.D. · Contactjohn.s.maddox.mil@health.mil · 301-295-4440
    • James Duncan, M.D. · Sub investigator
    • Eric Elster, M.D. · Sub investigator
    • Maria Paz Aquino, R.N. · Sub investigator
    • Sharon R May, R.N. · Sub investigator
    • Michael P McNally, M.D. · Principal investigator
    • John S Maddox, M.D. · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013 and a primary completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2013
First posted
May 20, 2013
Start
Mar 2013
Primary completionEst.
Dec 2014
Last update
May 20, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01857128
Lead sponsor
Walter Reed National Military Medical Center
Collaborators
United States Department of Defense
Responsible party
Michael P. McNally (Principal Investigator, Walter Reed National Military Medical Center) — Principal investigator
First posted
May 20, 2013
Start date
Mar 2013
Primary completion
Dec 2014 (estimated)
Last update
May 20, 2013

Study contacts

Michael P McNally, M.D.
Contact
301-295-4442
Michael P McNally, M.D.
principal investigator · Department of General Surgery

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion